ing nets, agricultural fungicides and rodent repellents. These widespread uses have resulted in the release of increasing amounts of organotins into the environment. In aquatic invertebrates, particularly marine gastropods, organotin compounds, such as tributyltin (TBT) and triphenyltin (TPT), induce irreversible sexual abnormality in females which is termed "imposex" at very low concentrations. Although it has been theorized that these compounds act as potential competitive inhibitors of aromatase, which converts androgen to estrogen, and then increase levels of unconverted androgens in gastropods, their effective concentrations for aromatase inhibition are high. In addition to wildlife, organotins may have various undesirable effects on human health. Contrary to the theory of organotin-induced aromatase inhibition in gastropods, in human choriocarcinoma cells, these compounds markedly enhance estradiol biosynthe-HSD I) activity, which converts low-activity estrogen estrone to the biologically more active form estradiol, at the same low concentrations. Although there are many reports describing the potential toxicity of organotins in human and mammals, the critical target molecules for the toxicity of organotin compounds are members of the nuclear receptor superfamily. Here, we review the potential genetics action and subsequent toxicity induced by organotins via these nuclear receptors.
INTRODUCTION
Organotin compounds, such as tributyltin (TBT) and triphenyltin (TPT), have been widely utilized as biocides, agricultural fungicides, wood preservatives, and disinfecting agents in circulating industrial cooling waters and in antifouling paints for marine vessels (Boyer, 1989; Fent, 1996) . Due to its widespread use as an antifouling agent in boat paints, organotin is a common contaminant of marine and freshwater ecosystems exceeding acute and chronic toxicity levels. Organotins are one of and consequently its environmental level, fate and toxicity are of current concern. The toxic potentials of organotins to various aquatic organisms are well documented. Especially, many studies dealing with the toxic effects of organotin compounds on sexual development and reproductive function are focused to gastropods. For example, very low concentrations of TBT and TPT induce irreversible sex-organ alterations in females, a phenomenon known as "imposex" (Horiguchi et al., 1997; Matthiessen and Gibbs, 1998) . These abnormalities are the result of a masculinization process by which male sex organs develop, notably a penis and a vas deferens. In certain species, growth of a vas deferens disrupts the structure and function of the oviducts, preventing normal breeding activity and causing population decline. Therefore, these organotins have been suspected as endocrine-disrupting chemi-cals to masculinize reproductive organs in not only invertebrates but also vertebrates.
POSSIBLE HUMAN EXPOSURE TO ORGANOTIN COMPOUNDS
Human exposure to non-point sources of organotins may occur mainly through contaminated dietary sources, TBT oxide (TBTO) determined in Japan by the duplicated-position method were 4.7 ± 7.0 μg/day in 1991 (n=39) and 2.2 ± 2.2 μg/day in 1992 (n=40). Using the marketbased method, the daily intake was estimated at 6~9 μg/ day in 1991 and 6~7 μg/day in 1992 (Tsuda et al., 1995) . In Finland, TPT were detected as the predominant comseafoods (Rantakokko et al., 2006) . In addition, a variety -taminating trialkyl species, are also prevalently used as bringing them into closer contact with drinking water and food supplies (Takahashi et al., 1999) .
The information on human exposure to organotin compounds is limited. In a study of eight volunteers from Germany, TPT was detectable in serum at the concentraet al., 2003) . In a study of 38 volunteers from the USA, Kannan et al. reported that monobutyltin (MBT), dibutyltin (DBT) and TBT were detected in 53, 81, and 70% of the 32 blood samples tested. Blood concentrations of MBT, DBT and TBT were 8.17 ± 8.56, 4.94 ± 3.83, and 8.18 ± 15.4 ng/ml, respectively (Kannan et al., 1999) . The toxicological significance of the concentrations of organotins measured in these studies is unknown. However, the potential exposure of humans to organotins has aroused great concern about their potential toxicity. Animal experiments suggested that the spectrum of potential adverse chronic systemic effects of organotins in humans is quite broad and includes primary immunosuppressive, endocrinopathic, neurotoxic metabolic, and enzymatic activity, as well as potential ocular, dermal, cardiovascular, upper respiratory, pulmonary, gastrointestinal, blood dyscrasias, reproductive/teratogenic/developmental, liver, kidney, bioaccumulative, and possibly carcinogenic activity. Although many reports have described the potential toxicity of organotins, the critical target molecules for the toxicity of organotin compounds remain unclear.
ORGANOTINS AS ENDOCRINE-DISRUPTING CHEMICALS
The synthesis of sex steroids from cholesterol requires -mic reticulum, and involves many enzymatic steps. Most of these steps use cytochrome P450 (CYP) haem-containing enzymes, and the genes coding for these enzymes are abbreviated to CYP (Fig. 1) . Some organotins compounds are known as endocrine-disrupting chemicals to modulate steroid hormone biosynthesis. As mentioned above, these organotins have been suspected to masculinize reproductive organs in vertebrates because, in some gastropods, very low concentrations of these organotins induce "imposex" (Horiguchi et al., 1997; Matthiessen and Gibbs, 1998) . Some evidences have theorized that enzyme which converts androgen to estrogen (Bettin et al., 1996; Matthiessen and Gibbs, 1998) . For example, exposure of the organotins increased testosterone levels in female gastropods and organotin-induced imposex can et al., 1996) . In addition, TBT was reported to be catalyzed to dibutyltin, which is a metabolite of TBT, by arounclear whether organotin compounds especially inhibit catalytic activity of aromatase in vertebrates.
Actually, can organotin compounds inhibit the catalytic activity of aromatase? The answer to the question seems to be 'Yes'. In in vitro experiments, butyltins are demonstrated to exhibit structure-related inhibition of the catalytic activity of human aromatase protein from human placenta (Heidrich et al., 2001) or transfected cells (Cooke, 2002) . However, at concentrations effective (micromolar level) for the inhibition of aromatase, TBT and TPT are generally toxic to mammalian cells because (Saitoh et al., 2001; Nakanishi et al., 2002; Watanabe et al., 2003; Nakanishi et al., 2006) . In human choriocarcinoma cell lines, JAr, JEG-3 and BeWo, exposure to greater than 300 nM TBT or TPT markedly decreases DNA and protein synthesis (Nakanishi et al., 2002; Nakanishi et al., 2006) . Concentrations under 1 μM of either organotin compound did isolated from human choriocarcinoma cells (Nakanishi et al., 2002) . In addition to aromatase, at above 1 μM, -ase I and II (Doering et al. et al., 2005) . At the same concentration ranges, TPT also inhibit the catalytic activity of , 2003) . These observations suggest that these organthe catalytic activity of aromatase and we have to consider the toxicity of organotin compounds in distinguishing -bition of steroidogenic enzymes.
In additon to these, sex steroid receptors and steroidogenic enzymes for sex steroid hormones have not whether sex steroid hormones are critical factors for sexual development and reproduction in gastropods. Furthermore, homologues of both the estrogen receptor (ER) and androgen receptor (AR) have not been found in invertebrates (Escriva et al., 2000) and the composition of nuclear receptor family members is very different between vertebrates and invertebrates (Escriva et al., 1997; Escriva et al., 2000) . Therefore, there is some doubt as to whether organotin compounds function as inhibitors of enzymes that metabolize androgens in gastropods, and this doubt led us to suspect that organotin compounds affect other target molecules in mammals.
ORGANOTIN COMPOUNDS AFFECT ENDOCRINE FUNCTIONS IN HUMAN PLACENTA AND OVARY
In a recent study, Nakanishi et al. investigated the effects of organotin compounds on aromatase activity (Nakanishi et al., 2002; Nakanishi et al., 2005) and activity estradiol (Nakanishi et al., 2006) , in human choriocarcinoma cells. Both TBT and TPT increased the cattheir mRNA expression in a dose-dependent fashion following exposure to non-toxic concentration ranges (3-100 nM). These results indicate that the observed organotin-induced alterations in human choriocarcinoma cells are due to the regulation of mRNA levels of both steroidogenic enzymes, not of the enzyme complex. In addition, these organotin compounds also markedly stimulated human chorionic gonadotropin (hCG) production in the same concentration ranges, along with its mRNA expression (Nakanishi et al., 2002; Nakanishi et al., 2005) . These results suggest that organotin compounds are potent stimulators of human placental estrogen biosynthesis and hCG production in vitro and that the placenta represents a potential target organ in pregnant women for organotin compounds, the endocrine-disrupting effects of which might be the result of local changes in estrogen and hCG concentrations.
In opposition to the above results, however, Saitoh et al. reported that 20 ng/ml (about 60 nM) TBT and TPT suppressed both the activity and gene expression of aromatase in the human ovarian granulose-like cell line, KGN (Saitoh et al., 2001) . This discrepancy in the action of organotins on the gene expression of human aromatase is due to the tissue-specific expression of aromatase, which is strictly regulated (Fig. 2) . Human CYP19 is a single-copy gene composed of 10 exons; exons II to X -lated region of mRNA common to all estrogen-producing tissues (Simpson et al., 1994) . A number of variations of various CYP19 mRNAs, which are selectively expressed in some tissues by alternative splicing (Simpson et al., 1994; Sebastian and Bulun, 2001; Bulun et al., 2003) . The CYP19 in humans appears to of the respective exon I sequences, and by transcription In ovarian granulosa cells, the expression of CYP19 is strongly regulated by the steroidogenic tissue-specific transcriptional factor, Ad4Bp/SF-1, via promoter II. In contrast, Ad4Bp/SF-1 is expressed at very low levels in the human placenta and may not play an important role in activation of the placental major promoter I.1 (Bamberger et al., 1996; Simpson et al., 1997) . Saitoh et al. suggest that the effects of organotin compounds in KGN cells are caused partly by association with Ad4Bp/SF-1 (Saitoh et al., 2001) . It is therefore likely that the action of organotin compounds in human placental cells is induced by a pathway clearly different from that in ovarian granulosa cells, giving rise to the promotion of aromatase activity and mRNA expression.
In human placental cells, all mRNA expressions of dependent intracellular signal pathways; however, neither TBT nor TPT exerted any effect on intracellular cAMP production (Nakanishi et al., 2002) . In addition, there is little possibility that these organotin compounds affect the cAMP-protein kinase A (PKA) pathway in the human ovary, because it stimulates aromatase gene expression through promoter II (Michael et al., 1995) . The possible target of these organotin compounds may be a signaling pathway common to the gene expression of aromatase,
RXR AGONISTS
Nuclear receptors play important roles in maintenance of the endocrine system, regulation of organ differentiation and fetal development. Reproductive abnormalities in wildlife can be associated with exposure to environmental pollutants capable of mimicking the action of natural hormones. As the nuclear receptors of intrinsic hormone systems are likely to be targets of industrial chemicals, information on their ability to bind these chemicals is valuable for environmental risk assessment. Recently, Kanayama et al. reported assay systems for human nuclear receptors to determine whether suspected endocrine disruptors can bind to members of the nuclear receptor family on the basis of the previously described CoA-BAP system (Kanayama et al., 2003) . Using these systems, they found that TBT and TPT were potential agonists of retinoid X receptor (RXR) and peroxisome proliferator-actiet al., 2005) . In addition, these compounds also induced the transactivation The effectiveness of each organotin compound was comparable to that of the natural ligand of RXR, 9-cis retin--itazone (Rosi) (Kanayama et al., 2005) . The dose ranges of TBT and TPT that induced transactivation were from or necrosis of mammalian culture cells in general. These results indicate that these organotin compounds function RXR stand out as unique members of the type II nuclear receptor subfamily and play dual roles in nuclear receptor signaling. On one hand, they can bind to their own response element (RXR response element) as a homodimer and activate transcription in response to their ligands, and on the other hand, they serve as partners for other nuclear receptors (Chambon, 1996; Giguere, 1994; Aranda and Pascual, 2001 ). The existence of three types of heterodimers-fully permissive, conditionally permiscase, PPARs/RXR, farnesoid X-activated receptor (FXR) exhibit dual ligand permissivity, because they can be activated by the agonists of either RXR or its partner receptor, or both, in a more-than-additive fashion (Kliewer et al., 1992; Issemann et al., 1993; Bardot et al., 1993; Mukherjee et al., 1997; Westin et al., 1998; Schulman et al. et al., 2000) . As an example of the second type, the RXR/ retinoic acid receptor (RAR) heterodimer exhibits conditional permissivity because a full response to RXR agonists occurs only in the presence of an RAR agonist (Westin et al., 1998; Germain et al., 2002) . The third type is the nonpermissive heterodimer, such as the RXR/thyroid hormone receptor and RXR/vitamin D receptor, which cannot be activated by RXR agonists regardless of the presence (or absence) of the agonist of its partner receptor; formation of the heterodimer is thought to actually preclude the binding of the ligand to RXR (Forman et al., 1995; Thompson et al., 1998) . TBT and TPT simulated the transactivation of an RXR -ic concentration ranges (10-100 nM), whereas they had no effect on the transactivation of RXR/TR and RXR/ RAR heterodimers . Although the effects of organotin compounds on the transactivation of have not been determined, it is probably possible to stim- Vol. 33 No. 3 ulate the transactivation of other heterodimers because these compounds function as RXR agonists.
REGULATION OF AROMATASE GENE EXPRESSION BY ORGANOTIN COMPOUNDS HUMANS
Gene expression of human aromatase is regulated by -centa, a selective RXR ligand stimulates aromatase gene -tle or no effect on aromatase gene expression (Sun et al., 1998; Nakanishi et al., 2005) . In addition, the PPAR lig-12,14 -prostaglandin J 2 (24), FXR ligand chenodeoxycholic acid (Nakanishi et al. ligand T0901317 (Nakanishi et al. unpublished data) , which are agonists of permissive heterodimer partners of RXR, all also failed to increase mRNA expression of aromatase in human choriocarcinoma cells. It is suggested that none of these pemissive heterodimers are involved in aromatase expression in the human placenta and that RXR homodimer may be required for the regulation of aromatase expression (Fig. 3) .
tive ligands suppress aromatase gene expression in the ovary (Mu et al., 2000; Mu et al., 2001; Fan et al., 2005) .
it promoter II lying upstream of the ovarian major exon I (PII) by an indirect mechanism because of the absence -matase (Mu et al., 2001) . A transcriptional factor, nuclear sequence of aromatase and up-regulates its gene expression in the human ovary. In addition, activation of the (Fan et al. - pathway (Fig. 3) . In light of these findings, human aromatase expression regulated by organotin compounds may involve Nakanishi et al., 2002; Nakanishi et al., 2005) , because the aromatase expression pattern induced in the human is similar to that induced by organotin compounds (Fig.  3) . It has already been found, as supporting evidence, that organotin compounds stimulate the expression of a luciferase reporter construct containing the human placental promoter I.1 sequence of aromatase via a ligand-dependent signaling pathway of RXR .
POTENTIAL TOXICITY BY ORGANOTIN ACTIVATION IN MAMMALS
class of synthetic antidiabetic agents, thiazolidinediones et al. used to treat type II diabetes and reverse insulin resistance in the whole body by sensitizing the muscle and liver tis--tial regulator of adipocyte differentiation and lipid storage in mature adipocytes (Tontonoz et al., 1994) . Unfortunate--sirable effects such as obesity. RXR agonists also activate -ing agonists in rodents (Mukherjee et al., 1997) , underagonists on diabetes and obesity. In light of these preet al. evaluated the effects of TPT and TBT on adipogenesis and found that these organotins stimulate the differentiation of preadipocyte 3T3-et al., 2005) . These results suggested that organotin compounds are a potential obesogen. A recent study from Grün et al. showed that, in vivo, acute exposure to TBT in adult mice resulted gene expression in adipose tissue and liver, and modulated adipocyte differentiation factors such as a members of the CCAAT/enhancer binding protein family and sterol regulatory element-binding protein 1c (Grün et al., 2006) . Furthermore, developmental exposure in utero led to a fatty liver (hepatic steatosis) phenotype and enhanced lipid staining of neonatal fat deposits, and resulting in a significant increase in the epididymal fat pad size of mice later in life (Grun et al., 2006) . Whether this occurs through increased lipid storage, an increase in adipocyte number, or a combination of both is currently unresolved. Howev--pounds represents a compelling mechanistic example of a class of environmental pollutants that have the ability to impact key adipogenic factors, fat deposit size and function.
Exposure of rats in utero to TBT induces a dramatic increase in the incidence of low-birth-weight fetuses because of maternal hypothyroidism (Adeeko et al., 2003) . On the other hand, the RXR agonist bexarotene with cutaneous T-cell lymphoma (Duvic et al., 2001) , -tive RXR agonist) induces the acute phase of hypothyet al., 2002) . Similarities between the toxicity of TBT and selective RXR agonists suggest that at least some of the toxic effects of organotin compounds may be mediated by RXR.
Yamabe et al. reported that TBT and TPT enhance the proliferation of androgen-dependent human prostate cancer cells and the transactivation of AR (Yamabe et al. mide cannot inhibit organotin-mediated AR transactivation (Yamabe et al., 2000) , and these organotin compounds do not function as AR agonists in a yeast two-hybrid system (Nishikawa et al. unpublished data) . Recently, RXR was found to function as a novel co-regulator of AR, and 9cRA was found to inhibit AR activity through the activation of RXR (Chuang et al., 2005) . It remains unclear whether the co-regulators recruited by organotin-activated RXR are different from those recruited by 9cRA, but RXR activation by organotins might be involved in the AR transactivation induced by them.
Taken together, these compounds may cause adverse or RXR because of the above-described toxic effects of organotin compounds in human cells and experimental animals.
CONCLUSIONS
Although organotin compounds inhibit the enzymatic activity of aromatase, their effective concentration is toxic for mammalian cells. In this review, we have proposed -nism for organotin-induced toxic effects in mammals. In addition, RXR are recently reported to play an important role in the development of gastropod imposex, by showing the cloning of an RXR homolog from a marine gastropod, binding of organotins to that receptor, and imposex induction by injection of 9cRA (Nishikawa et al., 2004; Castro et al. RXR activation is also a critical event for endocrine disruption of organotins in gastropods. However, it is possible that organotin compounds affect target molecules -pounds have been shown to enhance histone acetyltransferase activity (Osada et al., 2005) . Further studies are needed to clarify the precise action mechanism of the toxicity of organotin compounds in mammals in vitro and in vivo, because they appear intricate.
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